On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.

@article{Fordyce2016OnTreatmentOI,
  title={On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.},
  author={Christopher B. Fordyce and Anne S. Hellkamp and Yuliya V Lokhnygina and Samuel M Lindner and Jonathan P Piccini and Richard C. Becker and Scott D. Berkowitz and G{\"u}nter Breithardt and Keith A. A. Fox and Kenneth W. Mahaffey and Christopher C. Nessel and Daniel E. Singer and Manesh R. Patel},
  journal={Circulation},
  year={2016},
  volume={134 1},
  pages={
          37-47
        }
}
BACKGROUND Despite rapid clinical adoption of novel anticoagulants, it is unknown whether outcomes differ among patients with worsening renal function (WRF) taking these new drugs compared with warfarin. We aimed to determine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Apixaban by gest on Sptem er 4, 2017 http://ciajournals.org/ D ow nladed from Worsening Renal Function With Rivaroxaban Versus Warfarin Circulation. 2016;134:37-47

  • RD Lopes, JH Alexander, +12 authors ARISTOTLE Investigators
  • DOI: 10.1161/CIRCULATIONAHA.116.021890 July
  • 2016

Similar Papers

Loading similar papers…